APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy

Benzer Materyaller

• APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
  Yazar:: Viscusi ER, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-03-01)
• APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
  Yazar:: Singla, Neil K., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
  Yazar:: Singla, Neil, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
  Yazar:: Lambert, David, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways
  Yazar:: Schneider, Sebastian, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)